scholarly journals Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Juliana De Souza Rebouças ◽  
Irene Esparza ◽  
Marta Ferrer ◽  
María Luisa Sanz ◽  
Juan Manuel Irache ◽  
...  
Keyword(s):  
Allergen Immunotherapy ◽  
Allergic Diseases ◽  
Delivery Systems ◽  
Efficacy And Safety ◽  
Significant Progress ◽  
Reduced Dose ◽  
Promising Strategy ◽  
Polymeric Carriers ◽  
Local Side

In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.

scholarly journals Intrabullous Adhesion Pexia (IBAP) by Percutaneous Pulmonary Bulla Centesis: An Alternative for the Surgical Treatment of Giant Pulmonary Bulla (GPB)

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Wei-Liang Li ◽  
Yong-Hua Li ◽  
Yu-Bo Yang ◽  
Li-Hui Lv
Keyword(s):  
Exercise Tolerance ◽  
Size Range ◽  
Alternative Procedure ◽  
Efficacy And Safety ◽  
Viable Option ◽  
Promising Strategy ◽  
Invasive Method ◽  
The Mean

Background and Objective. Most patients with giant pulmonary bulla (GPB) are treated by surgery; however, there is a subset for whom surgery is not a viable option, such as those with contraindications, or those unwilling to undergo operation. Therefore, an alternative minimally invasive method is desired for this subpopulation. The aim of this study was to explore an alternative procedure for treating GPB. Methods. This was a prospective, nonrandomized, single-arm, unblinded study evaluating the efficacy and safety of intrabulla adhesion pexia (IBAP) procedure in GPB patients. The study was conducted between December 2004 and April 2017. Results. There were 38 cases in 36 patients (33 males and 3 females) with the target GPB cavities varying in size (range, 10 cm × 7 cm × 5 cm to 15 cm × 8 cm × 30 cm (anteroposterior diameter × medial-lateral diameter × superoinferior diameter)). After IBAP treatment, the closure ratio of GPB in one month was 86.84% (33/38), while the dyspnea index significantly decreased from 4.11 ± 1.11 to 2.24 ± 1.15 (P<0.01). In addition, the mean FEV1 (L) increased from 1.06 ± 0.73 to 1.57 ± 1.13 (P<0.01), while RV (L) decreased from 2.77 ± 0.54 to 2.36 ± 0.38 (P<0.01) and TLC (L) decreased from 6.46 ± 1.21 to 5.86 ± 1.08 (P<0.01). Moreover, PaO2 (mmHg) increased from 52.18 ± 8.31 to 68.29 ± 12.34, while the 6 MWD increased by 129.36% from 131.58 ± 105.24 to 301.79 ± 197.90 (P<0.01). Collectively, these data indicated significant improvement in pulmonary function and exercise tolerance after IBAP treatment. Furthermore, no deaths occurred during IBAP treatment, and no cases of aggravated GPB relapse were reported during the 12-month follow-up period. Conclusions. IBAP is a promising strategy for the treatment of GPB. Our findings demonstrated that IBAP had a noteworthy therapeutic effect, desirable safety, and ideal long-term efficacy for GPB.

The efficacy and safety of long-term administration of alpha-interferon and lamivudine in patients with chronic hepatitits B

2001 ◽  
Vol 120 (5) ◽  
pp. A572-A572
Author(s):  
F JABOLI ◽  
E RODA ◽  
C FABBRI ◽  
S MARCHETTO ◽  
F FERRARA ◽  
...  
Keyword(s):  
Alpha Interferon ◽  
Efficacy And Safety ◽  
Term Administration

ENDOSCOPIC TREATMENT OF CHRONIC PANCREATITIS IN PEDIATRIC POPULATION: LONG-TERM EFFICACY AND SAFETY

2019 ◽  
Author(s):  
D Kohoutova ◽  
A Tringali ◽  
G Paparella ◽  
V Perri ◽  
I Boškoski ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Endoscopic Treatment ◽  
Pediatric Population ◽  
Efficacy And Safety ◽  
Term Efficacy

Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1129-P
Author(s):  
SILVINA GALLO ◽  
BERNARD CHARBONNEL ◽  
ALLISON GOLDMAN ◽  
HARRY SHI ◽  
SUSAN HUYCK ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Efficacy And Safety ◽  
Term Efficacy

Desloratadine and levocetirizine – the importance in allergic diseases treatment

2020 ◽  
Vol 13 (3) ◽  
pp. 336-342
Author(s):  
Rafał Pawliczak
Keyword(s):  
Allergic Diseases ◽  
Efficacy And Safety ◽  
H1 Receptor ◽  
Receptor Blockers ◽  
Allergic Disorders

H1-receptor blockers (including levocetirizine and desloratadine) are employed in treatment of multiple allergic diseases. In this review we deliver data regarding efficacy and safety these two drugs. Moreover, we are comparing their properties. The individualization therapy is a mainstay in allergic disorders treatment.

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

2019 ◽  
Vol 3 ◽  
pp. S25
Author(s):  
Benjamin Ehst ◽  
George Han ◽  
Scott Guenthner ◽  
Kimberly Eads ◽  
Abby Jacobson
Keyword(s):  
Disease Duration ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document